Switzerland
-
-
Even though the Swiss franc/dollar cross currency swap has been trading in negative territory through January and February, Amgen, the US biotechnology company, made an impressive debut in Swiss francs this week with a seven year bond, the largest in the currency this year. -
UBS launched the first euro senior holdco deal of the year on Thursday and despite the trade’s strong reception and competitive pricing, bankers remain divided over whether more can follow.
-
Dutch lender, ABN Amro returned to the Swiss franc market on Friday with a 8.9 year note, making it the third FIG issuer this week to take advantage of arbitrage opportunities in this market.
-
Zurich Insurance sold a Sfr200m hybrid bond on Thursday, benefiting from the relative resilience of its home market as Swiss franc investors got their first taste of insurance capital this year.
-
Two FIG issuers this week took advantage of good conditions to tap the Swiss franc market, revealing an opportunity for other banks to escape widened euro and dollar spreads.
-
Marcel Koebeli, the country head of Switzerland at Barclays, has left the bank.
-
SpareBank 1 Nord-Norge took advantage of good conditions in Swiss francs on Thursday to print its second deal in the currency.
-
Goldman Sachs printed its largest ever deal in Swiss francs on Wednesday, revealing an opportunity for other banks escaping widened euro and dollar spreads.
-
Latin American supranational Corporacion Andina de Fomento received a warm welcome from asset managers and bank treasuries on its second outing of the month in the Swiss franc market on Tuesday.
-
Amgen, the US multinational bio-pharmaceutical company, on Monday announced plans for its debut bond in Swiss francs, a transaction that bankers hope could turn a gloomy February market around.
-
UBS priced its first Swiss franc-denominated senior bond issued out of the holding company on Monday.
